U.S. Markets
Johnson & Johnson (JNJ) commits USD 5.5bln to its talc litigation resolution, while resolution eliminates litigation of 76,000 of ovarian tout claims
StockNow breaking-news AI analysis
JNJ committed $5.5 billion to resolve 76,000 talc-related ovarian cancer claims, a move aimed at clearing a significant legal risk that has historically caused the stock to trade below its intrinsic value.
Related stocks
1 stocksWhat do investors think?
Curious what other investors think?Log in to see reactions and join the conversation.
Log in to view reactionsStockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.
